Ocuphire Pharma

Opus Genetics is a gene therapy company focused on addressing challenges related to the manufacturing of treatments for ultra-rare retinal degenerative diseases. By utilizing adeno-associated virus-based gene therapies, Opus aims to provide effective solutions for individuals suffering from blinding conditions. The company's patient-first approach emphasizes the importance of accessibility to these specialized treatments, ensuring that advancements in gene therapy reach those in need efficiently.

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other medical needs. The company's primary offerings include RX-3117, which is undergoing Phase IIa clinical trials for relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung, and cervical cancers. Other clinical-stage candidates include Archexin, an inhibitor of the protein kinase Akt, and Supinoxin (RX-5902), which targets various forms of cancer. In addition, the company is developing RX-0301 for hepatocellular carcinoma and has a robust preclinical pipeline featuring multiple anticancer drug candidates. Rexahn collaborates with various organizations, including academic institutions and biotechnology firms, to advance its research and development initiatives. Headquartered in Rockville, Maryland, the company aims to enhance patient outcomes by creating next-generation therapies that aim to improve efficacy while reducing the side effects commonly associated with cancer treatments.